.webp)
Australian companies Tetratherix and Epiminder bring new bone and epilepsy technologies to worldwide markets.
Tetratherix (ASX: TTX), a Sydney-based biotech, has announced plans to take its bone regeneration technology worldwide after establishing a special distribution arrangement with Nasdaq-listed Henry Schein Inc. The agreement opens the way for Tegenix, the company's first medicine, to enter the US market and other major markets. Henry Schein, the world's largest provider of healthcare solutions for dentists and medical professionals, will first focus on dental applications. Tegenix uses Tetratherix's Tetramatrix platform, a patented synthetic polymer technology created by CTO Dr. Ali Fathi at the University of Sydney. The platform is a liquid gel that expands at body temperature, providing a structure that promotes tissue growth while staying biocompatible.
According to the deal, Henry Schein will distribute Tegenix through its network in 33 countries. CEO Will Knox stated that the first shipments are planned in FY27, after FDA 510(k) clearance. Tetratherix is also developing a new manufacturing facility in Alexandria, Sydney, to increase production for dental and future clinical uses. Meanwhile, Melbourne-based med-tech company Epiminder achieved a milestone in the US with the first implant of its Minder System, an implantable device for epilepsy monitoring. The treatment took place at the Perelman School of Medicine at the University of Pennsylvania as part of the DETECT clinical research, which includes four other US institutions actively enrolling patients.
Epiminder aims to transform epilepsy diagnosis and care by combining years of scientific knowledge into practical patient solutions. This collaboration highlights Australia's growing worldwide reach in life sciences, showing how improved biomaterials and implanted neurotechnology could transform healthcare.
.webp)
.webp)
